By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neos Therapeutics 

2940 North Highway 360
Suite #400
Grand Prairie  Texas  75050  U.S.A.
Phone: 972-408-1300 Fax: 972-408-1143


SEARCH JOBS

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. Contact: HR@NeosTX.com.


Key Statistics


Email: HR@neostx.com
Ownership: Public

Web Site: Neos Therapeutics
Employees:
Symbol: NEOS
 




Segment
Drug Delivery





Company News
Neos Therapeutics (NEOS) To Present At 2017 UBS Global Healthcare Conference 5/16/2017 12:21:36 PM
Neos Therapeutics (NEOS) Reports First Quarter 2017 Financial Results 5/9/2017 10:40:45 AM
Neos Therapeutics (NEOS) Reports First Quarter 2017 Financial Results 5/9/2017 7:40:43 AM
Neos Therapeutics (NEOS) To Host First Quarter 2017 Financial Results Conference Call On May 9, 2017 5/2/2017 10:39:14 AM
Neos Therapeutics (NEOS) Reports Fourth Quarter And Full Year 2016 Financial Results 3/14/2017 10:45:34 AM
Neos Therapeutics (NEOS) Reports Fourth Quarter And Full Year 2016 Financial Results 3/14/2017 8:15:31 AM
Neos Therapeutics (NEOS) To Host Fourth Quarter And Year-End 2016 Financial Results Conference Call On March 14, 2017 3/8/2017 8:20:01 AM
Neos Therapeutics (NEOS) To Present At Cowen and Company 37th Annual Health Care Conference 2/28/2017 8:24:51 AM
Neos Therapeutics (NEOS) To Present At The RBC Capital Markets 2017 Global Healthcare Conference 2/16/2017 8:06:29 AM
Neos Therapeutics (NEOS) Announces Pricing Of Underwritten Public Offering Of $25 Million Of Common Stock 2/3/2017 7:15:18 AM
123456
//-->